Deferiprone

Iron Chelator — VARIOUS

Key facts

Deferiprone is an ofp drug in the Iron Chelator class catalogued in DrugCentral. It was first approved by the EMA in 1999. Its mechanism of action is classified as Iron Chelating Activity. DrugCentral lists 6 molecular targets, including KDM4A, KDM6A and DOHH. Recorded indications include beta Thalassemia and Iron overload.

• Approval status: ofp (first approved 1999 by the EMA).
• Drug class: Iron Chelator.
• Mechanism of action: Iron Chelating Activity.
• Molecular targets: KDM4A, KDM6A, DOHH and KDM5C (6 listed in DrugCentral).
• Indications: beta Thalassemia and Iron overload.
• ATC code: V03AC02 (Iron chelating agents).
• Molecular formula: C7H9NO2; molecular weight 139.15 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• beta Thalassemia
• Iron overload

Mechanism & targets

• Mechanism of action (MoA): Iron Chelating Activity
• Established pharmacologic class: Iron Chelator

Molecular targets (6)

Target	Gene	Action	Activity
Lysine-specific demethylase 4A	KDM4A	unknown	IC50 5.49
Lysine-specific demethylase 6A	KDM6A	unknown	IC50 5.38
Deoxyhypusine hydroxylase	DOHH	unknown	IC50 5.30
Lysine-specific demethylase 5C	KDM5C	unknown	IC50 5.25
Lysine-specific demethylase 2A	KDM2A	unknown	IC50 5.17
Lysine-specific demethylase 2B	KDM2B	unknown	IC50 5.09

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2011-10-14	FDA	—	APOPHARMA INC	Yes
1999-08-25	EMA	—	APOTEX EUROPE BV

ATC classification

ATC code	Therapeutic hierarchy
V03AC02	VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Iron chelating agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Agranulocytosis	451.5
Sickle cell anaemia with crisis	237.0
Neutropenia	138.4
Death	122.2
Off label use	119.4
Serum ferritin increased	113.1
Treatment noncompliance	88.2
White blood cell count decreased	43.7
Neuroleptic malignant syndrome	40.7
Nephrolithiasis	39.4
Neutrophil count decreased	36.1
Ill-defined disorder	34.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Deferiprone is on its molecule page.

• Molecular formula: C₇H₉NO₂
• Molecular weight: 139.15 g/mol
• CAS number: 30652-11-0
• InChIKey: TZXKOCQBRNJULO-UHFFFAOYSA-N
• PubChem CID: 2972

CN1C=CC(=O)C(O)=C1C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Deferiprone used for?

DrugCentral lists the following indications for Deferiprone: beta Thalassemia and Iron overload.

How does Deferiprone work?

Deferiprone is classified as Iron Chelating Activity; its molecular targets in DrugCentral include KDM4A, KDM6A, DOHH and KDM5C.

When was Deferiprone first approved?

Deferiprone was first approved by the EMA in 1999.

What drug class does Deferiprone belong to?

Deferiprone is in the Iron Chelator class.

What is the chemical formula of Deferiprone?

Deferiprone has the molecular formula C7H9NO2 and a molecular weight of 139.15 g/mol.

Sources

• DrugCentral drug card 4188 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL70927 — compound record and bioactivity
• PubChem CID 2972 — chemical identifiers
• DrugBank DB08826 — drug record
• FDA UNII 2BTY8KH53L — substance identity
• DailyMed: FDA labels for Deferiprone — current prescribing information (label search)
• UniProt O75164 (KDM4A) — target protein
• UniProt O15550 (KDM6A) — target protein
• UniProt Q9BU89 (DOHH) — target protein
• UniProt P41229 (KDM5C) — target protein
• UniProt Q9Y2K7 (KDM2A) — target protein
• UniProt Q8NHM5 (KDM2B) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.